IL-36R Inhibitor – Spesolimab Highly Effective in the treatment of PASH Syndrome: Clinical Case with General Evidence Analysis

Wiktor Kruczek; Kornelia Pietrauszka; Anna Tekielak; Beata Bergler-Czop

doi:10.5114/dr.2025.152307

Streszczenie

1/2025 vol. 112

Opis przypadku

IL-36R Inhibitor – Spesolimab Highly Effective in the treatment of PASH Syndrome: Clinical Case with General Evidence Analysis

Wiktor Kruczek ¹

,

Kornelia Pietrauszka ^{2, 3}

,

Anna Tekielak ^{2, 3}

,

Beata Bergler-Czop ²

Students‘ Scientific Association at the Department of Dermatology, School of Medicine in Katowice, Medical University of Silesia, Katowice, Poland
Chair and Department of Dermatology, Medical University of Silesia, Katowice, Poland
Doctoral School, Medical University of Silesia, Katowice, Poland

Dermatol Rev/Przegl Dermatol 2025, 112, 38-46

DOI: https://doi.org/10.5114/dr.2025.152307

Data publikacji online: 2025/05/15

Pełna treść artykułu

AMA

Kruczek W, Pietrauszka K, Tekielak A, Bergler-Czop B. IL-36R Inhibitor – Spesolimab Highly Effective in the treatment of PASH Syndrome: Clinical Case with General Evidence Analysis. Dermatology Review/Przegląd Dermatologiczny. 2025;112(1):38-46. doi:10.5114/dr.2025.152307.

APA

Kruczek, W., Pietrauszka, K., Tekielak, A., & Bergler-Czop, B. (2025). IL-36R Inhibitor – Spesolimab Highly Effective in the treatment of PASH Syndrome: Clinical Case with General Evidence Analysis. Dermatology Review/Przegląd Dermatologiczny, 112(1), 38-46. https://doi.org/10.5114/dr.2025.152307

Chicago

Kruczek, Wiktor, Kornelia Pietrauszka, Anna Tekielak, and Beata Bergler-Czop. 2025. "IL-36R Inhibitor – Spesolimab Highly Effective in the treatment of PASH Syndrome: Clinical Case with General Evidence Analysis". Dermatology Review/Przegląd Dermatologiczny 112 (1): 38-46. doi:10.5114/dr.2025.152307.

Harvard

Kruczek, W., Pietrauszka, K., Tekielak, A., and Bergler-Czop, B. (2025). IL-36R Inhibitor – Spesolimab Highly Effective in the treatment of PASH Syndrome: Clinical Case with General Evidence Analysis. Dermatology Review/Przegląd Dermatologiczny, 112(1), pp.38-46. https://doi.org/10.5114/dr.2025.152307

MLA

Kruczek, Wiktor et al. "IL-36R Inhibitor – Spesolimab Highly Effective in the treatment of PASH Syndrome: Clinical Case with General Evidence Analysis." Dermatology Review/Przegląd Dermatologiczny, vol. 112, no. 1, 2025, pp. 38-46. doi:10.5114/dr.2025.152307.

Vancouver

Kruczek W, Pietrauszka K, Tekielak A, Bergler-Czop B. IL-36R Inhibitor – Spesolimab Highly Effective in the treatment of PASH Syndrome: Clinical Case with General Evidence Analysis. Dermatology Review/Przegląd Dermatologiczny. 2025;112(1):38-46. doi:10.5114/dr.2025.152307.

Streszczenie

IL-36R Inhibitor – Spesolimab Highly Effective in the treatment of PASH Syndrome: Clinical Case with General Evidence Analysis

Udostępnij

Dostępne w

Zintergrowane z

Zasady redakcyjne